#United States #New York #class action lawsuit #Pomerantz Law Firm #INOVIO Pharmaceuticals

Class Action Filed Against Inovio Pharmaceuticals

In a significant legal development, Pomerantz LLP has announced the filing of a class action lawsuit against Inovio Pharmaceuticals, Inc., along with several of its officers. This lawsuit, which has been registered in the United States District Court for the Eastern District of Pennsylvania, raises pressing concerns for investors who acquired Inovio securities between October 10, 2023, and December 26, 2025.

The lawsuit alleges that Inovio and its officials made materially misleading statements regarding the company's operations and prospects, particularly related to their lead product candidate, INO-3107. This product aims to treat recurrent respiratory papillomatosis (RRP), a disease linked to human papillomavirus (HPV) infection. The firm claims that Defendants presented a rosy scenario about the potential for FDA approval, suggesting that the company would quickly transition into a commercially viable entity with products that could fill a vital medical need.

Background on Inovio Pharmaceuticals

Inovio is known for its focus on developing DNA medicines designed to treat diseases associated with HPV. Its approach combines DNA plasmids—tiny DNA molecules that instruct the body to produce proteins targeting diseases—and a proprietary medical device, CELLECTRA, to facilitate the delivery of these treatments into cells effectively. Investors were particularly interested in the INO-3107 BLA (Biologics License Application), as Defendants frequently cited the prospects of receiving expedited FDA approval.

Allegations of Misleading Statements

Throughout the class period, the lawsuit contends that Inovio's leadership made numerous assertions about the efficiency of the CELLECTRA device and the anticipated timeline for FDA submission. However, the reality was starkly different, as the lawsuit argues that manufacturing issues plagued the device, rendering the FDA submission timeline unrealistic. The complaint points out that Inovio failed to disclose critical deficiencies in its operations, leading investors to believe in an overstated potential for timeline and approval.

The turning point came on August 8, 2024, when Inovio informed the market of a significant delay in their FDA submission due to these manufacturing issues. This revelation resulted in a sharp decline in the company's stock price, reflecting investor disappointment and loss of confidence.

Another blow arrived on December 29, 2025, with the announcement that the FDA would not expedite the review of the INO-3107 BLA due to insufficient information provided by Inovio, resulting in a substantial drop in stock value once again.

Investor Actions and Future Considerations

As part of the ongoing legal process, investors who purchased Inovio securities during the specified class period are being urged to take action. They have until April 7, 2026, to apply to the court to be appointed as Lead Plaintiff, which is crucial for representing the collective interests of all affected investors. The suit aims not only to recover damages but also to ensure transparency and accountability from Inovio's management regarding the actual business conditions and risks involved.

Pomerantz LLP is recognized as a leading firm in class action litigation, particularly within the realms of corporate securities and antitrust laws. Their commitment to advocating for victims of securities fraud establishes them as a key player in the advocacy for investors' rights, having recovered billions in claims against corporate misconduct over the years.

As this situation continues to develop, investors and industry observers alike will be watching closely to see how it unfolds and what implications it may carry for not only Inovio but also similar biotechnology firms in an increasingly scrutinized market.